1. Home
  2. CCNE vs OMER Comparison

CCNE vs OMER Comparison

Compare CCNE & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNB Financial Corporation

CCNE

CNB Financial Corporation

HOLD

Current Price

$26.88

Market Cap

736.3M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$10.93

Market Cap

628.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCNE
OMER
Founded
1865
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
736.3M
628.9M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
CCNE
OMER
Price
$26.88
$10.93
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$29.00
$27.50
AVG Volume (30 Days)
101.9K
1.7M
Earning Date
10-30-2025
11-13-2025
Dividend Yield
2.67%
N/A
EPS Growth
N/A
N/A
EPS
1.91
N/A
Revenue
$227,923,000.00
N/A
Revenue This Year
$13.84
N/A
Revenue Next Year
$27.68
N/A
P/E Ratio
$14.11
N/A
Revenue Growth
5.27
N/A
52 Week Low
$19.32
$2.95
52 Week High
$28.30
$13.60

Technical Indicators

Market Signals
Indicator
CCNE
OMER
Relative Strength Index (RSI) 69.72 71.76
Support Level $25.78 $9.31
Resistance Level $26.20 $10.41
Average True Range (ATR) 0.63 0.80
MACD 0.21 0.17
Stochastic Oscillator 89.88 99.89

Price Performance

Historical Comparison
CCNE
OMER

About CCNE CNB Financial Corporation

CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. It derives revenue through the operations as a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. The company branch are located in Pennsylvania, Ohio, New York and Virginia.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: